Zhi Tong Cai Jing·2025-09-15 09:43Core Viewpoint - The company, Zhaoyan New Drug (603127), experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in September 2025, prompting an investigation into the reasons behind this abnormal trading behavior [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external business environment that would affect the stock price [1]. - There is no undisclosed major information that could impact the stock price [1]. Group 2: Major Events - The company conducted a self-examination and consulted with its controlling shareholders and actual controllers, confirming that there are no major events affecting stock price fluctuations, such as major asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially impact the stock price [3]. Group 4: Sensitive Information - The company verified that there were no transactions involving the company's stock by its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].